Everest Ventures

Legendsemi is a company dedicated to the development and design of high-performance analog and mixed-signal chips. It specializes in creating mid-to-high-end digital-analog hybrid products, focusing on the research and development of semiconductor solutions that primarily involve high-precision signal chains and signal chain microcontrollers or system-on-chips. Through its innovative approach, Legendsemi aims to deliver advanced technology that meets the demands of modern electronic applications.

Evrynet is a developer of an advanced financial services platform that facilitates the creation of centralized and decentralized finance (CeDeFi) applications. The company's infrastructure utilizes blockchain technology to offer fundamental financial templates, serving as a foundation for more complex financial functions and decentralized finance applications. Evrynet's platform incorporates smart contracts, allowing both individuals and enterprises to easily develop financial applications that are interoperable with various leading blockchains. This capability enables a seamless integration of diverse financial services, catering to the needs of developers and businesses in the evolving landscape of finance.

XCarnival is a crypto influencer focused on developing innovative financial services. It specializes in constructing non-standard asset leasing, pawning, and lending platforms.

7SIGNAL specializes in enterprise wireless network monitoring. Its cloud-based platform continuously assesses wireless networks, pinpointing elusive issues affecting application performance. By focusing on the 'edge' of networks where user experience is crucial, it enhances employee productivity and operational efficiency. Deployed globally across Fortune 500 companies, hospitals, and large venues.

Suzhou Ribo Life Science focuses on developing nucleic acid therapeutics using RNA interference (RNAi) technology. The company advances RNAi-based drug discovery, including siRNA design and screening, chemical modification and delivery technologies, and pharmacokinetic and safety evaluation, through to clinical trials. It targets liver-related diseases, including Hepatitis B, liver fibrosis and liver cancer, as well as breast cancer and HIV. The company operates from Kunshan, China, and was founded in 2007. It has pursued strategic partnerships, notably with Quark Pharmaceuticals, to advance its RNAi programs.